ESTROGEN RECEPTOR-POSITIVE BREAST CANCER
Clinical trials for ESTROGEN RECEPTOR-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ESTROGEN RECEPTOR-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for ESTROGEN RECEPTOR-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for seniors: breast cancer combo shows promise in older patients
Disease control CompletedThis study looked at how well older adults (70+) with advanced, hormone-sensitive breast cancer tolerate a combination of palbociclib and either letrozole or fulvestrant. The goal was to see if the treatment is safe and effective in this age group. 93 participants were enrolled, …
Matched conditions: ESTROGEN RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug duo shows promise for hard-to-treat cancers
Disease control CompletedThis early-phase trial tested a new drug called ALRN-6924 combined with the chemotherapy paclitaxel in 28 adults with advanced solid tumors that had spread or couldn't be removed by surgery, including a type of breast cancer. The main goal was to find the safest dose and check fo…
Matched conditions: ESTROGEN RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for Hard-to-Treat breast cancer? alisertib combo tested
Disease control CompletedThis phase II trial tested the drug alisertib, alone or combined with fulvestrant, in 96 postmenopausal women with advanced breast cancer that no longer responds to hormone therapy. Alisertib blocks enzymes that help cancer cells grow, while fulvestrant blocks estrogen. The goal …
Matched conditions: ESTROGEN RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New combo therapy shows promise in preventing breast cancer return
Disease control CompletedThis study looked at whether shutting down the ovaries (ovarian suppression) combined with hormone therapy (tamoxifen or exemestane) could better prevent breast cancer from coming back in premenopausal women with hormone-sensitive breast cancer. Over 3,000 women who had surgery t…
Matched conditions: ESTROGEN RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug combo shows promise for advanced breast cancer
Disease control CompletedThis study tested a combination of two drugs, palbociclib and tamoxifen, as the first treatment for people with a certain type of advanced breast cancer (HR-positive, HER2-negative). The goal was to see how long the cancer could be kept from growing. 49 participants took both pil…
Matched conditions: ESTROGEN RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Oana Danciu, MD • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Could a short course of radiation before surgery spare more breast tissue?
Disease control CompletedThis pilot study tested whether giving a high dose of focused radiation (APBI) to the tumor before surgery is feasible for older women with early-stage, hormone-sensitive breast cancer. Twenty-two participants received radiation followed by a lumpectomy. The goal was to see if th…
Matched conditions: ESTROGEN RECEPTOR-POSITIVE BREAST CANCER
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Keto diet plus breast cancer drug shows promise in small study
Symptom relief CompletedThis early-phase study tested whether a 2-week very low-carbohydrate (ketogenic) diet combined with the drug letrozole is feasible and tolerable for people with early-stage estrogen receptor-positive (ER+) breast cancer. 31 postmenopausal women participated before surgery. The go…
Matched conditions: ESTROGEN RECEPTOR-POSITIVE BREAST CANCER
Phase: EARLY_PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC